Georgia State University Reports Findings in Small Interference RNAs (siRNAs) (Fab'-bearing siRNA TNF alpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis)
By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Small Interference RNAs (siRNAs) have been presented. According to news reporting originating from Atlanta, Georgia, by NewsRx correspondents, research stated, "Patients suffering from inflammatory bowel disease (IBD) are currently treated by systemic drugs that can have significant side effects. Thus, it would be highly desirable to target TNF alpha siRNA (a therapeuticmolecule) to the inflamed tissue."
Our news editors obtained a quote from the research from Georgia State University, "Here, we demonstrate that TNF alpha siRNA can be efficiently loaded into nanoparticles (NPs) made of poly (lactic acid) poly (ethylene glycol) block copolymer (PLA-PEG), and that grafting of the Fab' portion of the F4/80 Ab (Fab'-bearing) onto the NP surface via maleimide/thiol group-mediated covalent bonding improves the macrophage (MP)-targeting kinetics of the NPs to RAW264.7 cells in vitro. Direct binding was shown between MPs and the Fab'-bearing NPs. Next, we orally administered hydrogel (chitosan/alginate)-encapsulated Fab'-bearing TNF alpha-siRNA-loaded NPs to 3% dextran sodium sulfate (DSS)-treated mice and investigated the therapeutic effect on colitis. In vivo, the release of TNF alpha-siRNA-loaded NPs into the mouse colon attenuated colitis more efficiently when the NPs were covered with Fab'-bearing, compared to uncovered NPs. All DSS-induced parameters of colonic inflammation (e.g., weight loss, myeloperoxidase activity, and I kappa b alpha accumulation) were more attenuated Fab'-bearing NPs loaded with TNF alpha siRNA than without the Fab'-bearing. Grafting the Fab'-bearing onto the NPs improved the kinetics of endocytosis as well as the MP-targeting ability, as indicated by flow cytometry."
According to the news editors, the research concluded: "Collectively, our results show that Fab'-bearing PLA-PEG NPs are powerful and efficient nanosized tools for delivering siRNAs into colonic macrophages."
For more information on this research see: Fab'-bearing siRNA TNF alpha-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. Journal of Controlled Release, 2014;186():41-53. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
The news editors report that additional information may be obtained by contacting H. Laroui, Georgia State University, Center Inflammat Immun & Infect, Atlanta, GA 30303, United States. Additional authors for this research include E. Viennois, B. Xiao, B.S.B. Canup, D. Geem, T.L. Denning and D. Merlin (see also Small Interference RNAs (siRNAs)).
Keywords for this news article include: Atlanta, Georgia, Therapy, Genetics, Immunology, Macrophages, Nanoparticle, United States, Myeloid Cells, Nanotechnology, Gastroenteritis, Colonic Diseases, Gastroenterology, Experimental Colitis, Emerging Technologies, Connective Tissue Cells, North and Central America, Digestive System Diseases, Gastrointestinal Diseases
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC